ENMD was mentioned in this NLAB PR today. Could that be enough to push it up? Anyway, I did buy a couple more ENMD puts today.
Edit - Too early with the puts as it turns out...
====
Nuoncology Labs' Findings Accepted for Presentation At
Cancer Research Conference
VIRGINIA BEACH, Va.--(BW HealthWire)--Feb. 23, 1999--
Molecular Biologist Joins Research Team
NuOncology Labs, Inc. (OTC BB:NLAB) announced today that
the results of the validation and testing of scientific data on
the Company's lead cancer treatment drug, Arglabin, have
been accepted for presentation at the Annual Conference of
the American Association for Cancer Research (AACR) in
Philadelphia on April 10, 1999.
Over 300 patients with a variety of cancers have been
treated with Arglabin with very promising results and few
side effects. Published data show that Arglabin inhibits or
stops the growth of several types of tumors, both alone and
in combination with other compounds ("Arglabin. Its
Structure, Properties, and Usage," Institute of
Phytochemistry, Republic of Kazakstan, 1997).
U.S. patents have been filed for Arglabin, related compounds
and the mechanism of action of the compounds. The first
group of claims filed have recently been allowed by the U.S.
Patent and Trademark Office. The pending patents are held in
two subsidiary companies, Paracure, Inc., and the
International Phytochemistry Research Laboratory, Ltd., of
which NuOncology Labs owns 50 percent and 80 percent,
respectively. Arglabin, a plant-derived compound, is already
approved for cancer treatment in special clinics in Kazakstan
and other republics of the former Soviet Union.
The AACR, a scientific society of over 13,000 laboratory and
clinical cancer researchers, was founded in 1907 to facilitate
research, discussion and dissemination of knowledge among
scientists and others dedicated to the cancer problem; and to
advance the understanding of cancer etiology, prevention,
diagnosis, and treatment throughout the world.
The AACR publishes four prestigious journals; convenes an
annual meeting attended by more than 7,500 scientists from
around the world; organizes several highly focused scientific
conferences each year; and offers a variety of educational
and training programs in support of its mission.
In December, NuOncology Lab's scientists successfully
completed their validation of data generated by the Institute
of Phytochemistry and the Cancer Curing Hospital in
Karaganda, Kazakstan, on the mechanism of action of
Arglabin.
Arglabin was studied by a team headed by Tattym Shaikenov,
Ph.D., from the Institute of Molecular Biology and
Biochemistry at Almaty University, Kazakstan. Over the past 2
years, Dr. Shaikenov has conducted additional experiments at
The Center for Biotechnology, Old Dominion University in
Virginia and at NuOncology Labs in Houston, Texas.
To further the Company's research efforts and to strengthen
its scientific team, NuOncology Labs has recently engaged
molecular biologist Nagindra Prashad, Ph.D. Dr. Prashad
received his Ph.D. from The University of Houston in 1970.
After postdoctoral studies at the University of California,
Berkley and at the Southwest Medical School in Dallas, he
began his research career in molecular biology and oncology
in 1980, as Assistant Professor in the Graduate School of
Biomedical Sciences at the University of Texas, Health
Science Center in Houston. In 1990, Dr. Prashad joined
Aprogenex, Inc., in Houston, Texas, where he developed DNA
probe technology for the diagnosis of genetic diseases, HIV,
and cancer.
As consultant to NuOncology Labs in 1998, Dr. Prashad made
valuable contributions to the studies elucidating the
mechanism of action of Arglabin. Now, Dr. Prashad will play
important roles in NuOncology Labs' anti-cancer drug
development program and development of sensitive cancer
diagnostics. Dr. Prashad is inventor on 11 patents, and author
on 20 peer reviewed publications.
NuOncology Labs, Inc. participates in the multi-billion dollar
cancer treatment industry, along with companies such as
Entremed (NASDAQ: ENMD), Covance (NYSE: CVD), Quest
Diagnostics (NYSE: DGX), and Labonne (NASDAQ: LABS).
NuOncology Labs engages in research, development, testing
and licensing of promising cancer treatments. In its clinical
laboratory business, the company conducts predictive drug
response tests for the optimization of contemporary cancer
treatment.
Note: Statements in this document that are not descriptions
of historical facts are forward-looking and subject to risks and
uncertainties.
Actual results could differ materially from those currently
anticipated due to a number of factors, including risks
relating to the early state of products under development;
uncertainties relating to clinical trials; dependence on third
parties; future capital needs; and risks relating to the
commercialization, if any, of the Company's proposed
products (such as marketing, safety, regulatory, patent,
product liability, supply, competition and other risks).
NuOncology Labs, Inc. trades on the OTC Electronic Bulletin
Board under the symbol "NLAB." |
